Kockelmann et al. - Version V3

1	Chemical/technical risk analysis of a new multidirectional nebulizer (MDN)
2	and its clinical implementation for the safe administration of
3	Pressurized Intraperitoneal Aerosol Chemotherapy (MDN-PIPAC)
4	
5	Short title:
6	MDN-PIPAC is feasible and safe
7	
8	Fabian Kockelmann, MD ¹ , Daniel Göhler, DiplIng. ^{2,3} , Sarah Barbey ⁴ , Mehdi Ouaissi, Prof.
9	MD, PhD ^{5,6,} Jürgen Zieren, Prof, MD ^{1,} Urs Giger-Pabst, Prof, MD ^{5,7}
10	
11	¹ Department of Surgery, Klinikum Dortmund, Hospital of the Witten/Herdecke University,
12	Germany
13	² Topas GmbH, Dresden, Germany
14	³ Research Group Mechanical Process Engineering, Institute of Process Engineering and
15	Environmental Technology, Technische Universität Dresden, Dresden, Germany
16	⁴ Plateforme Pixanim, INRAE PRC, 37380, Nouzilly, France
17	⁵ EA4245 Transplantation, Immunologie, Inflammation, Université de Tours, France
18	⁶ Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver
19	Transplant Surgery, University Hospital of Tours, France
20	⁷ Fliedner Fachhochschule, University of Applied Sciences, Düsseldorf, Germany
21	
22	
23	
24	Correspondence:
25	Professor Urs Giger-Pabst, MD
26	Fliedner Fachhochschule
27	University of Applied Sciences Düsseldorf, Germany
28	Phone: +49 (0) 163 729 44 07
29	Email: ursgiger@gmx.net

Kockelmann et al. - Version V3

30 KEY WORDS

- 31 PIPAC, Multi-directional nebulizer (MDN), chemical compatibility, chemical risk analysis,
- 32 CT-peritoneography, clinical safety, feasibility

33

34 ABBREVIATIONS

- 35AETAnalytical Evaluation Threshold (ISO 10993-18 (2020)
- 36 BSA Body Surface Area calculated according to DuBois
- 37 CE Conformité Européenne
- 38 DGAV Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie
- 39 ECOG Eastern Cooperative Oncology Group
- 40 FDA U.S. Food and Drug Administration
- 41 GC-MS Gas Chromatography coupled with Mass Spectrometry
- 42 HSGC-MS Head-space Gas Chromatography coupled with Mass Spectrometry
- 43 IC Ion Chromatography
- 44 ICP-OES Inductively Coupled Plasma Atomic Emission Spectrometry
- 45 LC-MS Liquid phase chromatography coupled to a Mass Spectrometer
- 46 MDN Multi-Directional Nebulizer (Quattro JetTM, REGER, Medizintechnik
- 47 GmbH, Villigendorf, Germany)
- 48 PCI Peritoneal Carcinomatosis Index according to Sugarbaker
- 49 PIPAC Pressurized IntraPeritoneal Aerosol Chemotherapy
- 50 PSM Peritoneal Surface Malignancies
- 51 RIPAC Rotational intraperitoneal aerosol chemotherapy

Kockelmann et al. - Version V3

- 52 SDN Single direction nebulizer
- 53 HD/HP PIPAC High dosage/high pressure pressurized intraperitoneal chemotherapy

54

55 AUTHOR CONTRIBUTIONS

56 Fabian Kockelmann, Urs Giger-Pabst: study design, coordination of study, data acquisition,

57 data interpretation, logistics, drafting of manuscript and critical revision for important content

58 of the manuscript

- 59 Daniel Göhler and Mehdi Ouaissi: drafting of the manuscript and intellectual and scientific
- 60 contributions depending on their field of expertise
- 61 Sarah Barbey: study protocol, coordination of animal experiments and perioperative62 management of animals
- ⁶³ Jürgen Zieren: study design, PIPAC procedures, data acquisition, data interpretation, logistics,
- 64 drafting of manuscript and critical revision for important content of the manuscript

65

66 **DISCLOSURE**

All authors have no conflicts of interest or financial ties to disclose. The animal experiments, were funded by the Association Tourangelle de recherche en oncologie du val de Loire (AT-ROVL). All data produced in the present study are available upon reasonable request to the authors All data produced in the present study are available upon reasonable request to the authors.

72

Kockelmann et al. - Version V3

74 MINI ABSTRACT

Toxicological analyses confirm that doxorubicin, cisplatin and oxaliplatin nebulized with the MDN do not release leachables that pose a toxicological risk to patients. Through technical risk analysis and PIPAC simulations, a safety concept for the administration of MDN-PIPAC was established. No technical/medical intraoperative adverse events were observed. The perioperative course was comparable to that of the conventional axial single-direction nebulizer (SDN) PIPAC.

81

82 ABSTRACT

Background/Aim: To test the chemoresistance of a multi-directional nebulizer (MDN) and to
establish and implement a perioperative clinical safety concept for its clinical use to deliver
pressurised intraperitoneal aerosol chemotherapy (MDN-PIPAC).

Study design: Ex-vivo nebulization of cytostatic drugs with the MDN device to assess chemoresistance/toxicological risks. Establishment of a perioperative safety concept for the clinical administration of MDN-PIPAC by ex- and in-vivo porcine simulation studies. Unicentric case series of 30 MDN-PIPACs in patients with peritoneal surface malignancies (PSM). Endpoints were intraoperative adverse events and perioperative complications (Clavien-Dindo).

Results: Toxicological studies/risk assessment confirm the safety of administering PIPAC with the MDN. The horizontal nozzles must protrude at least 7 mm beyond the most distal end of the trocar tip and lateral tilting should be prevented by fixation of the device in a single-arm holder. A total of 21 patients (male/female ratio: 2:1) with a mean age of 62 (range: 38-86) years underwent 30 consecutive MDN-PIPACs for peritoneal surface malignancies of different origin. ECOG 0 and 1 were seen in five and 16 patients,

Kockelmann et al. - Version V3

98 respectively. Thirteen, seven and one patient underwent one, two and three MDN-PIPACs, 99 respectively. Two patients received only one cycle of MDN-PIPAC because they were 100 considered candidates for cytoreductive surgery and heated intraperitoneal chemotherapy. 101 There were no intraoperative technical/medical problems observed. Four patients suffered 102 from postoperative grade I complications. 103 *Conclusions*: Compounds leached during chemotherapy nebulization with the MDN are

toxicologically safe. MDN-PIPAC administration is safe and the postoperative coursecomparable to that of the conventional PIPAC nebulizer.

106

107 **1.0 INTRODUCTION**

108 For more than a decade, pressurised intraperitoneal aerosol chemotherapy (PIPAC) has been 109 used worldwide for the treatment of peritoneal surface malignancies (PSM). Clinical results 110 have been encouraging, but data from prospective randomised trials clearly demonstrating the 111 efficacy of this treatment are still lacking [1 - 3]. A common feature of all currently available 112 nebulizers for PIPAC is that all nebulizers have only one atomizing unit (axial single-113 direction nebulizer (SDN)), which ejects the chemotherapy droplets in an axial direction. The 114 majority (97.5% by volume) of the nebulized chemotherapy directly impacts with the 115 peritoneum located below the atomizer orifice [4]. It has also been suggested that the locally 116 high drug deposition that occurs with the use of conventional PIPAC nebulizers leads to 117 potential local toxicity that could result in an increase in perioperative complications, 118 especially when additional surgical procedures such as complex adhesiolysis or bowel 119 resection are performed concurrently with PIPAC [5 - 7]. However, recent clinical data seem 120 to relativise an increased complication rate with PIPAC and concomitant extended surgery 121 [8]. However, for such reasons, PIPAC nebulizer technology has been extended by integrating 122 three additional atomizer units into the nebulizer head in the horizontal plane at a distance of

Kockelmann et al. - Version V3

123 120 degrees. Initial ex-vivo data from such multi-directional nebulizer (MDN) report an 124 improved spatial drug distribution [2, 9].

125 For some time now, a CE approved MDN has been available for clinical off-label PIPAC use 126 (MDN-PIPAC). However, since there are still no documented in-vivo applications worldwide, 127 we have decided to conduct additional extensive preclinical testing before the first clinical 128 application. The aim of this study was to i) investigate any toxicological risk posed by 129 leachables from the device when used in conjunction with cytotoxic drugs, ii) develop an 130 intraoperative safety concept for the administration of MDN-PIPAC using an ex-vivo PIPAC 131 model, in-vivo animal CT-peritoneography and iii) retrospective analysis of a consecutive 132 case series of 30 patients to evaluate the perioperative safety of MDN-PIPAC in patients with 133 peritoneal surface malignancies (PSM).

- 134
- 135

2.0 **MATERIAL & METHODS**

136 2.1 *Research sites and institutes:* Nebulization for cytostatic drug compatibility/toxicology 137 studies of the MDN and the in-vivo animal experiments were carried out at the French 138 National Research Institute for Agriculture, Food and Environment (INRAE), Centre Val de 139 Loire Nouzilly, France. Chemical characterisation and toxicological evaluation by 140 RESCOLL, Pessac, France and TentaConsult Pharma & Med GmbH, Münster, Germany, 141 respectively. The ex-vivo MDN-PIPAC simulation studies and the Schlieren investigations 142 were carried out at the Bauhaus University Weimar, Germany.

143 2.2 MDN chemotherapy compatibility study: Doxorubicin, cisplatin and oxaliplatin were 144 purchased from Hexal AG, Holzkirchen, Germany, Accord Healthcare B.V. Utrecht, The 145 Netherlands and Medac GmbH, Wedel, Germany. Drug doses (doxorubicin 6 mg, cisplatin 30 146 mg and oxaliplatin 120 mg per m^2 of body surface area (BSA)) were studied according to data 147 of phase I safety studies and clinical use [10 - 12]. A patient with a height of 1.90 m and a

Kockelmann et al. - Version V3

148 weight of 100 kg was assumed as scenario. The BSA was calculated according to the DuBois 149 formula [13]. Glucose 5% and NaCl 0.9% were purchased from B. Braun, Melsungen, 150 Germany. Oxaliplatin was diluted with glucose 5%, doxorubicin and cisplatin with NaCl 151 0.9% to a total of 50 ml and 150 ml, respectively. For blank control solution, doxorubicin 152 1.368 mg was diluted with 5 ml of 0.9% NaCl 0.9% and cisplatin 6.84 mg diluted with 15 ml 153 of 0.9% NaCl 0.9% to a total volume 20 ml. Oxaliplatin 36.48 mg was diluted with 20 ml of 154 5% Glucose. Blank control solutions were immediately filled into sterile glass bottles (ref. # 155 FRAA-250-60, Labbox GmbH, Düsseldorf, Germany) and stored protected from light at 4 °C. 156 The chemotherapy solutions for nebulization experiments were filled into syringes (ELS 200 157 ml (S), MEDTRON AG, Saarbrücken, Germany), the syringe instated into the high-pressure injector head (Accutron[®] HP-D Vision, MEDTRON AG, Saarbrücken, Germany), vented and 158 then connected to the high-pressure line of the MDN (Quattro JetTM, REGER Medizintechnik 159 160 GmbH, Villigendorf, Germany). The shaft of the MDN was wrapped with sterile surgical 161 compress proximal to the head of the nebulizer and then positioned vertically in a tight and 162 stable position in the neck of a sterile 250 ml glass bottle (ref. # FRAA-250-60, Labbox 163 GmbH, Düsseldorf, Germany). Nebulization could take place unhindered with the nebulizer 164 head in the body of the bottle at a flow rate of 1.5 ml/s with an upper pressure limit of 300 psi. 165 Nebulization was undertaken under a vertical laminar air flow bench. Doxorubicin and 166 Cisplatin were nebulized one after the other but into the sample bottle. All experiments were 167 performed in triplicates. The sample and blank control solution bottles were sealed air tight 168 immediately after the experiments and stored protected from light at 4°C. Transport of the 169 samples to the laboratory for further processing by courier within 4 hours while refrigeration 170 was maintained.

2.3 Chemical characterisation and toxicological risk assessment: The MDN device was
 categorised according to ISO 10993-1:2018 and the chemical characterisation was performed

Kockelmann et al. - Version V3

173 according to ISO 10993-18:2020. Head-Space Gas Chromatography coupled with Mass 174 Spectrometry (HSGC-MS) were used for detection of volatile organic compounds, Gas 175 Chromatography coupled with Mass Spectrometry (GC-MS) for detection of semi volatile 176 organic compounds, Liquid Phase Chromatography coupled to a Mass Spectrometer (LC-177 MS) for detection of non-volatile organic compounds, Inductively Coupled Plasma Atomic 178 Emission Spectrometry (ICP-OES) for quantification of the inorganic elements and Ion 179 Chromatography (IC) for quantification of the ions. The Analytical Evaluation Threshold 180 (AET) according to ISO 10993-18:2020 was applied. AET defines the threshold below which 181 leachable or extractable substances cannot be identified or quantified and therefore it can be 182 assumed without further evaluation that such a substance does not pose a toxicological risk.

183 The parameters used for the toxicological risk assessment were set to consider the worst case. 184 Three consecutive MDN-PIPAC administrations were assumed with no time interval in 185 between (instead of a treatment interval of four to six weeks between each PIPAC cycle). In 186 addition, the exposure of children with a body weight of 10 kg was calculated with the 187 amount used for the treatment of an adult. The toxicological risk associated with leachables 188 was assessed by collecting data and identifying critical health endpoints through literature 189 searches and toxicological risk assessment from PubChem (HSDB), PubMed, ChemIDplus, 190 ECHA databases and various other online sources and databases (e.g., FDA.gov) in 191 accordance with ISO 10993-17:2002

192 2.4 Preclinical assessment of the MDN-PIPAC safety checklist and Schlieren imaging: As 193 a first step, a team of two surgeons and one PIPAC nurse analysed whether the use of the 194 MDN could result in additional intraoperative risks or hazards for healthcare personnel. 195 Potential risks were assessed for clinical relevance. Appropriate safety measures were then 196 developed and integrated into our existing intraoperative PIPAC safety checklist [14]. In order 197 to check whether a mispositioning of the MDN head in the trocar shaft could lead to a

Kockelmann et al. - Version V3

possible retrograde leakage of chemotherapy aerosol into the environment, we additionally performed ex-vivo streaking studies on an established PIPAC model [15]. In a second step, using this adapted intraoperative PIPAC safety checklist, the team repeatedly simulated MDN-PIPAC applications in the operating room using NaCl 0.9% (B. Braun, Melsungen, Germany) on an established ex-vivo PIPAC model [15] to test the coherence of the adapted intraoperative PIPAC safety measures and the safety checklist. In summary, a final intraoperative MDN-PIPAC safety checklist was developed for in- vivo animal experiments.

205 2.5 In-vivo animal MDN-PIPAC and CT-peritoneography:

206 Domestic pigs were handled and cared for according to all relevant guidelines by authorised 207 investigators. The study (file # 40583) was approved by the French Ministry of Higher 208 Education and Research (Ministère de l'enseignement supérieur et de la recherche). A total of 209 three male animals weighing from 47 to 42 kg were used. Anaesthesia was induced by 210 intramuscular injection of ketamine 20 mg/kg, xylazine 2 mg/kg, and a subcutaneous injection 211 of atropine 0.02 mg/kg, and then completed by endotracheal intubation. Animals were 212 maintained under anaesthesia by isoflurane 3%, intravenous sufentanil, and cisatracurium. 213 The animals were fixed in a supine position in the CT-scanner (SOMATOM Definition AS 214 128, Siemens, Germany) to deliver HP/HD PIPAC described previously [12]. The MDN was 215 placed at the centre of the abdomen in a perpendicular position so that the horizontal nozzle 216 openings protruded approx. 7 mm beyond the end of the 12-mm trocar. The orientation of 217 these horizontal nozzle openings was chosen so that one nozzle was directed into the right and 218 left upper abdomen and the third nozzle into the small pelvis. Another 5-mm trocar was 219 inserted into the abdominal cavity to monitor the position of the nozzle head with a 5 mm 220 camera and the nebulization process. CT-peritoneography was performed using a modified technique previously described [16]. For this purpose, 100 ml Imeron[®] 300 (Bracco Imaging 221 222 GmbH, Konstanz, Germany) was diluted in 900 ml NaCl 0.9% (B Braun, Melsungen,

Kockelmann et al. - Version V3

Germany) in a ratio of 1:10. 150 ml of this solution was then administered for HP/HP-PIPAC CT-peritoneography at a flow rate of 1.5 ml/s (Accutron CT-D Vision, MEDTRON AG, Saarbrücken, Germany). CT-peritoneography was performed immediately at the end of HP/HD-PIPAC. After CT acquisition, the animals were immediately euthanized by intravenous injection of phenobarbital.

228 2.6 Patients' selection criteria for MDN-PIPAC: The clinical study was performed in line 229 with the guidelines of the Declaration of Helsinki at the Department of Surgery, Klinikum 230 Dortmund, University Hospital of the University Witten/Herdecke, Germany. All patients 231 gave oral and written informed consent. For the clinical trial, the approval of the Ethics 232 Committee of the Medical Faculty of the University of Münster/Medical Association 233 Westphalia-Lippe in Germany (file # 2021-360-f-s) and the German Clinical Trials Register 234 at https://www.drks.de/DRKS00033077 was obtained.

235 All patients had histologically confirmed primary or metastatic peritoneal surface 236 malignancies (PSM). Patients were selected by a multidisciplinary tumor board accredited by 237 the German Society for General and Visceral Surgery (DGAV). The inclusion criteria have 238 already been described in detail [10]. The time interval between cycles was between four to 239 six weeks. Systemic chemotherapy was discontinued one week prior and after MDN-PIPAC. 240 Patients were informed that PIPAC treatment was not provided within the framework of 241 evidence-based therapy guidelines. All patients gave their oral and written consent. All 242 procedures were performed as previously described in detail [10, 12] and were performed by one senior surgeon (J.Z.). Oxaliplatin at a dose of 120.0 mg/m^2 body surface area (BSA) 243 244 diluted in a total of 150 ml glucose 5% was administered in case of PSM of colorectal and appendiceal primary tumours. For all other tumour entities, doxorubicin 6.0 mg/m² BSA 245 diluted in 50 ml NaCl 0.9% followed by cisplatin 30.0 mg/m² BSA diluted in 150 ml NaCl 246 247 0.9% [10 - 12]. According to the manufacturer's instructions for use, the MDN was operated

Kockelmann et al. - Version V3

at a liquid fluid volume flow of 1.5 ml/s with an upper pressure limit of 300 psi. Access to the

249 peritoneal cavity was always obtained via an infraumbilical open Hasson approach. Before 250 starting the drug nebulization, the capnoperitoneal pressure was increased from 12 to 20 251 mmHg and then kept constant for 30 minutes. 252 2.7 Perioperative short-term outcome and data acquisition: Retrospective data acquisition 253 of a consecutive case series of 30 patients. The entire staging laparoscopy, including 254 documentation of the Sugarbaker PCI score, the amount of ascites and the quality of 255 chemotherapy nebulization, is monitored by video according to our standards for 256 intraoperative documentation. All data are stored electronically in the patient's record. Data 257 acquisition and data base management is carried out by J. Z. as part of the required quality 258 assurance as a certified centre of the DGAV. Perioperative adverse events are graded 259 according to the Clavien-Dindo Classification [13, 14]. Data are expressed as absolute 260 numbers whereas continuous data are expressed as medians (range).

261

248

262 **3.0 RESULTS**

3.1 Chemical characterisation and toxicological risk assessment: The results of the
chemical analyses of nebulized chemotherapy solutions are summarized in Table 1.

The independent systematic toxicological risk assessment based on the assumption of three consecutive PIPAC sessions on the same day in a child with a body weight of 10 kg revealed no toxicological risk for the few compounds detected after nebulization.

3.2 Preclinical technical, safety checklist and surgical approach assessment for MDNPIPAC: The following three relevant sub-areas were defined and perioperative measures
implemented as follows:

Kockelmann et al. - Version V3

271 3.2.1 *Operational parameters:* According to previous research data and the manufacturer's 272 specifications, the MDN is operated best with pressure of 150-250 psi with an upper 273 safety limit pressure of 300 psi. In practice this pressure operating window 274 corresponds to the liquid volume flowrate of 1.2 ml/s - 1.6 ml/s. [2]. Accordingly, 275 these operating parameters were stored in the high-pressure injector as a separate 276 MDN-PIPAC working programme. As there are no other differences in handling and 277 technical operation compared to the conventional nebulizer used, no additional 278 measures were necessary.

279 3.2.2 *Construction & Design:* Due to the three horizontal nozzles, there is a potential risk of 280 drug nebulization in the trocar if the horizontal nozzles are not placed sufficiently 281 beyond the distal end of the trocar into the abdominal cavity. In the worst case, 282 retrograde leakage of chemotherapy through the trocar valve into the operating theatre 283 could occur and harm healthcare workers. To avoid this, the correct positioning of the 284 nebulizer head in the trocar has been added to our standard safety checklist. The four-285 eye principle is used to check that the horizontal nozzles extend beyond the most distal 286 point of the trocar. It should be noted that most trocars are bevelled at an angle of 287 approximately 15°. The most distal end of the trocar is therefore used as the reference 288 point (Figure 1A).

3.2.3 Surgical approach: To optimize spatial aerosol distribution during MDN-PIPAC, the spraying distance between the nozzle orifice and the peritoneum should be as large as possible [2, 7]. Periumbilical, perpendicular placement of the MDN is therefore ideal, if surgically possible (Figure 2A). Additionally, we decided to orientate the MDN in that way that one horizontal spray jet pointed to the right upper and a second to the left upper abdominal quadrant and the third towards the small pelvis (Figure 2B). In addition, we decided to routinely fix the nebulizer intraoperatively in a single-arm

Kockelmann et al. - Version V3

holder (M-TRAC, Braun, Melsungen, Germany) to further prevent tilting and axial
sliding in the trocar. The central periumbilical perpendicular MDN position as well as
the orientation of the horizontal nozzle orifices were integrated into our intraoperative
safety checklist.

300 2.3 Ex-vivo MDN-PIPAC simulation and Schlieren imaging: As the distal end of the 301 trocar is angled, special care must be taken to ensure that the distal end of the trocar is visible 302 intraoperatively so as not to interfere with the nebulization of the horizontal nozzles. The 303 correct position of the MDN head has therefore been included as a separate item in our 304 extended safety checklist. The openings of the horizontal nozzles must extend at least 7 mm 305 beyond the distal end of the trocar to avoid interference during nebulization (Figure 1 A). In 306 addition, the vertical position of the MDN in the 10/12-mm trocar was found to cause the 307 MDN to tend to slide inward in the trocar without additional fixation. To avoid MDN slippage 308 into the trocar, the device is placed on the trocar head with a rubber ring (sterile, reusable 309 trocar seal) previously pulled over the shaft of the nebulizer in such a way that the rubber ring 310 fits tightly on the trocar head and prevents the nebuliser from slipping inside the trocar 311 (Figure 1 B). To further stabilize the position of the MDN, the use of a single-arm holder 312 turned out to be essential and was therefore also included in our safety checklist. In addition, 313 it was investigated whether a mispositioning of the MDN head with the horizontal nozzles 314 nebulizing in the trocar shaft could cause aerosol leakage into the environment but multiple 315 simulations of such a scenario showed visually no detectable retrograde aerosol leakage into 316 the environment.

317 2.4 In-vivo pig MDN-PIPAC CT-peritoneography: The CT-peritoneographies of the three 318 pigs could be performed without perioperative complications. The animals showed no 319 cardiorespiratory problems due to the capnoperitoneal pressure of 20 mmHg. Our previously 320 prepared MDN-PIPAC safety checklist was implemented without any problems. The

Kockelmann et al. - Version V3

321	subsequent CT-peritoneographies showed an excellent distribution pattern of the administered
322	contrast agent aerosol. However, no contrast agent was visible in the ventral portions of the
323	abdominal cavity. Figure 3 depicts representative images of pig N° 1.
324	2.5 Clinical baseline characteristics: A total of 21 patients (male/female ratio: 2:1) with a
325	mean age of 62 (range: 38-86) years underwent 30 consecutive MDN-PIPACs. ECOG 0 and 1
326	were seen in five and 16 patients, respectively. Patients had PSM of the upper gastrointestinal
327	tract (n = 6), ovarian cancer (n = 4), colorectal cancer (n = 3), hepato-pancreatico-biliary tract
328	(n = 3), malignant epithelioid peritoneal mesothelioma $(n = 2)$ and other $(n = 3)$. Eleven
329	patients had metachronous PSM. Prior to MDN-PIPAC, seventeen patients had undergone
330	primary tumor resection. The median number of patients had 2 (range: 1-5) lines of systemic
331	chemotherapy before undergoing MDN-PIPAC. Seven patients had previously undergone a
332	median of 2 (range: 1 - 4) PIPACs with the conventional PIPAC nebulizer in our institutions.
333	The patients' preoperative baseline data are listed in Table 2.

334 2.6 *MDN-PIPAC procedure details, morbidity, and mortality:* Abdominal access was 335 achieved in all patients. Thirteen, seven and one patient underwent one, two and three MDN-336 PIPACs, respectively. Two patients received only one cycle of MDN-PIPAC because they 337 were considered candidates for cytoreductive surgery (CRS) and heated intraperitoneal 338 chemotherapy (HIPEC) at the time of staging laparoscopy for MDN-PIPAC.

The median Sugarbaker PCI score and ascites at the first MDN-PIPAC were 25 (1-35) and 200 ml (0 - 800ml), respectively. The overall mean (range) operative time was 52.3 (48 - 78) minutes. The gradual pressure build-up and the subsequent exposure phase of 30 minutes at a capnoperitoneal pressure of 20 mmHg were well tolerated. No patient showed signs of cardiorespiratory impairment from the procedure. No intraoperative surgical or technical problems occurred.

Kockelmann et al. - Version V3

345 In total, four patients suffered grade I (Dindo-Clavien) complications after a total of 30 MDN-346 PIPACs (4/30). Three patients experienced persistent nausea and vomiting postoperatively, 347 requiring prolonged intravenous rehydration and antiemetic therapy (without gastric tube) for 48 hours postoperatively. Another patient complained of abdominal pain, which could also be 348 349 managed after extending intravenous analgesic therapy. No complications > grade 1 were 350 observed. The German health system requires a minimum hospitalization of 3 days for PIPAC 351 application in order to be fully reimbursed by the health insurance companies. All patients 352 were discharged on the third postoperative day at home.

353

354 4.0 DISCUSSION

355 For more than a decade, a PIPAC nebulizer has been available for off-label clinical use. This 356 technology, with an axially mounted nebulizer unit, has become the standard PIPAC device. 357 Due to its design and performance characteristics, the distribution pattern of the atomized 358 chemotherapy is not homogeneous. Below the opening of the nebulizer unit, approximately 359 97% by volume is deposited directly onto the underlying peritoneum by inertial impaction [4, 360 19 - 22]. Recently, other PIPAC nebulizers have become available on the market. However, 361 all nebulizers are based on the same/similar design as the standard technology. Therefore, the 362 problem of local chemotherapy accumulation and inhomogeneous drug distribution pattern in 363 the peritoneal cavity remains unresolved [2], which may affect the oncological efficacy of 364 PIPAC [23]. Therefore, the optimal position of the standard PIPAC nozzle has been 365 investigated in recent years in order to optimize the spatial distribution of chemotherapy [14, 366 24, 25]. More recently, new experimental PIPAC nozzle technologies have been developed. 367 Rotational intraperitoneal pressure aerosol chemotherapy (RIPAC) uses a modified nebulizer 368 technology similar to the standard PIPAC nebulizer. However, to optimize drug distribution, 369 the nozzle rotates 30° around its vertical axis in the abdominal cavity. In-vivo large animal

Kockelmann et al. - Version V3

data indicate, that RIPAC leads to a significantly more homogeneous distribution pattern and
higher penetration depths of doxorubicin into the tissue compared to the standard PIPAC [26,
27]. Another experimental approach is the use of a preclinical multi-directional nebulizer
(MDN). Braet et al. observed in an ex-vivo PIPAC model that the use of their experimental
MDN device improved the spatial drug distribution of nebulized nanoparticles compared to
standard PIPAC technology [28].

Based on these experimental data, it seems obvious that PIPAC nozzles, which optimize drug
distribution, could also be promising in clinical application. For some time now, a FDA and
CE Class IIa certified MDN has been available for off-label clinical use of MDN-PIPAC [2].
We carried out extensive preclinical testing before introducing this new device into our daily
practice.

381 After the premature discontinuation (https://clinicaltrials.gov/study/NCT04065139) of a 382 French prospective, randomized phase II study (PIPAC EstoK 01) [29], it was vividly 383 discussed whether toxic substances could arise during the application of PIPAC due to the 384 interaction of the chemotherapy solution with the PIPAC nebulizer/syringe/tube system. 385 Therefore, independent toxicological investigations were performed as a first step. For the 386 worst-case scenario with the highest chemotherapy doses, the toxicological investigations showed that no relevant toxicologically questionable substances were observed. The risk 387 388 assessment was further based on the assumption that three PIPACs are administered 389 consecutively on one day to a patient with a body weight of 10 kg. Even this extreme scenario 390 did not reveal any cumulative toxicological risk for patients. Furthermore, these data indicate 391 that the MDN device could also be used in children with a body weight > 10 kg. It is 392 important to emphasize that our toxicological data are only valid for this type of nozzle. 393 According to our current knowledge, there are no data available for other types of nebulizers.

Kockelmann et al. - Version V3

394 Our further technical analysis with PIPAC surgeons and scrub nurses in our department 395 showed that the handling of the MDN differs only slightly from that of the standard nebulizer. 396 The MDN unit requires a higher flow rate which can been programmed into the high-pressure 397 injector. However, a major difference is the three additional nozzles built horizontally into the 398 MDN head. Repetitive ex vivo simulations have shown that the correct mounting of the 399 nozzle head is crucial. The lateral openings of the nebulizers must protrude at least 7 mm 400 beyond the distal end of the trocar for correct atomization. Moreover, we observed that the 401 MDN can slip into the trocar due to the increased weight of the device. Therefore, we have 402 added a sterile rubber ring to the MDN that is pulled over the nozzle and positioned so that it 403 rests directly on the trocar head, while at the same time achieving the ideal position for the 404 MDN head. Finally, another important safety point is the consistent use of a single-arm 405 holder, which additionally fixes the MDN in a strictly vertical position in the trocar. This 406 measure also prevents the MDN from unintentionally tilting sideways during the spraying 407 process, which could worsen the spatial distribution pattern of the drug. In order to better 408 monitor this correct position intraoperatively, it would be desirable if the manufacturer could 409 provide a safety mark indicating intraoperatively the ideal position of the MDN head. The 410 manufacturer was informed of these points to improve the administrability and safety of 411 MDN-PIPAC.

To further refine the intraoperative MDN-PIPAC safety checklist, based on our previous exvivo simulations, we performed MDN-PIPAC in the large animal model immediately followed by CT-peritoneography to visualize the quality of the spatial aerosol distribution. The administration of all three MDN-PIPACs went without any technical or safety problems. The CT-peritoneographies revealed wide aerosol deposition. In particular, areas such as the omental bursa, hepatic interlobar and deep entero-enteric regions were also affected. Only the ventral parts of the abdominal cavity showed no contrast. However, large gravity-dependent

Kockelmann et al. - Version V3

fluid collections, as previously observed with the conventional PIPAC technique, did notoccur [22].

The clinical application of the elaborated intraoperative MDR-PIPAC safety checklist enabled us to apply the procedure to thirty consecutive patients without intraoperative problems. The postoperative course was characterized by four patients with minor complications (Dindo-Clavien grade I). Based on this initial experience, no clinical difference from conventional PIPAC was observed at our institution [12].

426 5.0 CONCLUSION

427 Toxicological data show that the use of the MDN does not generate any leachable substances 428 that could pose a risk to patients. Ex-vivo simulations confirm the importance of correct 429 positioning and fixation of the MDN in the trocar and, if possible, in a periumbilical position. 430 Ex-vivo streak tests show that chemotherapy aerosol does not escape from the trocar valve 431 into the operating room even if the MDN head is incorrectly positioned in the trocar shaft. 432 MDN handling is safe and poses no problems if the safety checklist is properly adapted to this 433 device. Whether such new devices will have a positive impact on clinical outcomes remains 434 uncertain. However, the superior spatial distribution of nebulized substances may have a 435 positive effect on clinical outcome. It is unlikely that there will be prospective studies in the 436 near future to clarify this issue. Therefore, we suggest that the type of nebulizer used for 437 PIPAC should also be documented in the ISSPP PIPAC database [30]. Such a large database could provide insight into the role of different nebulizers used on oncological outcome. 438

Kockelmann et al. - Version V3

439 **REFERENCES**

- Di Giorgio A, Macrì A, Ferracci F, Robella M, Visaloco M, De Manzoni G, Sammartino
 P, Sommariva A, Biacchi D, Roviello F, Pastorino R, Pires Marafon D, Rotolo S, Casella
 F, Vaira M. 10 Years of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): A
 Systematic Review and Meta-Analysis. Cancers. 2023; 15(4):1125.
- 444 <u>https://doi.org/10.3390/cancers15041125</u>
- 445 2. Daniel Göhler, Kathrin Oelschlägel, Mehdi Ouaissi, Urs Giger-Pabst. Performance of
- different nebulizers in clinical use for Pressurized Intraperitoneal Aerosol Chemotherapy
- 447 (PIPAC). medRxiv 2023.03.24.23287646; doi:
- 448 https://doi.org/10.1101/2023.03.24.23287646
- 449 3. Nadiradze G, Horvath P, Sautkin Y, Archid R, Weinreich F-J, Königsrainer A, Reymond
- MA. Overcoming Drug Resistance by Taking Advantage of Physical Principles:
 Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). Cancers. 2020; 12(1):34.
 https://doi.org/10.3390/cancers12010034
- 453 4. Göhler D, Khosrawipour V, Khosrawipour T, Diaz-Carballo D, Falkenstein TA, Zieren J,
 454 Stintz M, Giger-Pabst U. Technical description of the microinjection pump (MIP®) and
- granulometric characterization of the aerosol applied for pressurized intraperitoneal
 aerosol chemotherapy (PIPAC). Surg Endosc. 2017 Apr;31(4):1778-1784. doi:
 10.1007/s00464-016-5174-5. Epub 2016 Sep 8. PMID: 27631320.
- 5. Tempfer CB, Rezniczek GA, Ende P, Solass W, Reymond MA. Pressurized
 Intraperitoneal Aerosol Chemotherapy with Cisplatin and Doxorubicin in Women with
 Peritoneal Carcinomatosis: A Cohort Study. Anticancer Res. 2015 Dec;35(12):6723-9.
- doi: 10.1055/s-0035-1560004. PMID: 26637888.
- 462 6. Tavernier C, Passot G, Vassal O, Allaouchiche B, Decullier E, Bakrin N, Alyami M,
- 463 Davigo A, Bonnet JM, Louzier V, Paquet C, Glehen O, Kepenekian V. Pressurized
- 464 intraperitoneal aerosol chemotherapy (PIPAC) might increase the risk of anastomotic

Kockelmann et al. - Version V3

465		leakage compared to HIPEC: an experimental study. Surg Endosc. 2020 Jul;34(7):2939-
466		2946. doi: 10.1007/s00464-019-07076-3. Epub 2019 Aug 27. PMID: 31456025.
467	7.	Davigo A, Passot G, Vassal O, Bost M, Tavernier C, Decullier E, Bakrin N, Alyami M,
468		Bonnet JM, Louzier V, Paquet C, Allaouchiche B, Glehen O, Kepenekian V. PIPAC
469		versus HIPEC: cisplatin spatial distribution and diffusion in a swine model. Int J
470		Hyperthermia. 2020;37(1):144-150. doi: 10.1080/02656736.2019.1704891. PMID:
471		32003300.
472	8.	Graversen M, Rouvelas I, Ainsworth AP, Bjarnesen AP, Detlefsen S, Ellebaek SB,
473		Fristrup CW, Liljefors MG, Lundell L, Nilsson M, Pfeiffer P, Tarpgaard LS, Tsekrekos A,
474		Mortensen MB. Feasibility and Safety of Laparoscopic D2 Gastrectomy in Combination
475		with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Gastric
476		Cancer at High Risk of Recurrence-The PIPAC-OPC4 Study. Ann Surg Oncol. 2023 Mar
477		3. doi: 10.1245/s10434-023-13278-w. Epub ahead of print. PMID: 36867174.
478	9.	Braet, Helena and Andretto, Valentina and Mariën, Remco and Yücesan, Beyza and
479		Haegebaert, Ragna and Lollo, Giovanna and De Smedt, Stefaan C. and Remaut, Katrien,
480		The Effect of Electrostatic High Pressure Nebulization (ePIPAC) on the Stability, Activity
481		and Ex Vivo Distribution of Ionic Self-Assembled Nanomedicines. Available at SSRN:
482		https://ssrn.com/abstract=4418821 or http://dx.doi.org/10.2139/ssrn.4418821
483	10	. Guowei Kim, Hon Lyn Tan, Raghav Sundar, Bettina Lieske, Cheng Ean Chee, Jingshan
484		Ho, Asim Shabbir, Maria V. Babak, Wee Han Ang, Boon Cher Goh, Wei Peng Yong,
485		Lingzhi Wang and Jimmy B.Y. So. PIPAC-OX: A Phase I Study of Oxaliplatin-Based
486		Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases.
487		Clin Cancer Res April 1 2021 (27) (7) 1875-1881; DOI: 10.1158/1078-0432.CCR-20-
400		2152

Kockelmann et al. - Version V3

- 489 11. Robella M, De Simone M, Berchialla P, Argenziano M, Borsano A, Ansari S, Abollino O,
- 490 Ficiarà E, Cinquegrana A, Cavalli R, Vaira M. A Phase I Dose Escalation Study of
- 491 Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal
- 492 Carcinomatosis. Cancers (Basel). 2021 Mar 3;13(5):1060. doi: 10.3390/cancers13051060.
- 493 PMID: 33802269; PMCID: PMC7958944.
- 494 12. Ramos Arias G, Sindayigaya R, Ouaissi M, Buggisch JR, Schmeding M, Giger-Pabst U,
- 495 Zieren J. Safety and Feasibility of High-Pressure/High-Dose Pressurized Intraperitoneal
- 496 Aerosol Chemotherapy (HP/HD-PIPAC) for Primary and Metastatic Peritoneal Surface
- 497 Malignancies. Ann Surg Oncol. 2022 Nov 18. doi: 10.1245/s10434-022-12698-4. Epub
- 498 ahead of print. PMID: 36400887.
- 499 13. Du Bois, D. and Du Bois, E.F. (1916) A Formula to Estimate the Approximate Surface
- Area if Height and Weight Be Known. Archives of Internal Medicine, 17, 863-871.
 http://dx.doi.org/10.1001/archinte.1916.00080130010002
- 502 14. Giger-Pabst U, Tempfer CB. How to Perform Safe and Technically Optimized Pressurized
- 503 Intraperitoneal Aerosol Chemotherapy (PIPAC): Experience After a Consecutive Series of
- 504 1200 Procedures. Journal of Gastrointestinal Surgery: Official Journal of the Society for
- 505 Surgery of the Alimentary Tract. 2018 Dec;22(12):2187-2193.
- 506 15. Solaß, W., Giger-Pabst, U., Zieren, J. et al. Pressurized Intraperitoneal Aerosol
- 507 Chemotherapy (PIPAC): Occupational Health and Safety Aspects. Ann Surg Oncol 20,
- 508 3504–3511 (2013). <u>https://doi.org/10.1245/s10434-013-3039-x</u>
- 509 16. Meyers, M.A. (1976). Peritoneography: Normal and Pathologic Anatomy. In: Dynamic
- 510 Radiology of the Abdomen. Springer, New York, NY. https://doi.org/10.1007/978-1-
- 511 4757-3955-8_3
- 512 17. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new
 513 proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg.

Kockelmann et al. - Version V3

514	2004	Aug:240(2):205-13.	doi:	10.1097/01.	sla.0000133083.	.54934.ae.	PMID:	15273542;

- 515 PMCID: PMC1360123.
- 516 18. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, 517 518 Cameron JL, Makuuchi M. The Clavien-Dindo classification of surgical complications: 519 five-year experience. Ann Surg. 2009 Aug;250(2):187-96. doi: 520 10.1097/SLA.0b013e3181b13ca2. PMID: 19638912.
- 521 19. Khosrawipour V, Khosrawipour T, Diaz-Carballo D, Förster E, Zieren J, Giger-Pabst U.

522 Exploring the Spatial Drug Distribution Pattern of Pressurized Intraperitoneal Aerosol

523 Chemotherapy (PIPAC). Ann Surg Oncol. 2016 Apr;23(4):1220-4. doi: 10.1245/s10434-

524 015-4954-9. Epub 2015 Nov 9. PMID: 26553440.

- 20. Axel Davigo, Guillaume Passot, Olivia Vassal, Muriel Bost, Clément Tavernier, Evelyne 525 526 Decullier, Naoual Bakrin, Mohammad Alyami, Jeanne-Marie Bonnet, Vanessa Louzier, 527 Christian Paquet, Bernard Allaouchiche, Olivier Glehen & Vahan Kepenekian (2020) 528 PIPAC versus HIPEC: cisplatin spatial distribution and diffusion in a swine model, 37:1, 529 International Journal of Hyperthermia, 144-150, DOI: 530 10.1080/02656736.2019.1704891
- 531 21. Giger-Pabst U, Bucur P, Roger S, Falkenstein TA, Tabchouri N, Le Pape A, Lerondel S,
 532 Demtröder C, Salamé E, Ouaissi M. Comparison of Tissue and Blood Concentrations of
 533 Oxaliplatin Administrated by Different Modalities of Intraperitoneal Chemotherapy. Ann
 534 Surg Oncol. 2019 Dec;26(13):4445-4451. doi: 10.1245/s10434-019-07695-z. Epub 2019
 535 Aug 9. PMID: 31399820.
- 536 22. Bellendorf A, Khosrawipour V, Khosrawipour T, Siebigteroth S, Cohnen J, Diaz-Carballo
 537 D, Bockisch A, Zieren J, Giger-Pabst U. Scintigraphic peritoneography reveals a non538 uniform 99mTc-Pertechnetat aerosol distribution pattern for Pressurized Intra-Peritoneal

Kockelmann et al. - Version V3

- 539 Aerosol Chemotherapy (PIPAC) in a swine model. Surg Endosc. 2018 Jan;32(1):166-174.
- doi: 10.1007/s00464-017-5652-4. Epub 2017 Jun 22. PMID: 28643076.
- 541 23. Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration:
- 542 tissue penetration and surface exposure. J Natl Cancer Inst. 1997 Apr 2;89(7):480-7. doi:
- 543 10.1093/jnci/89.7.480. PMID: 9086004.
- 544 24. Khosrawipour V, Khosrawipour T, Falkenstein TA, Diaz-Carballo D, Förster E, Osma A,
- 545 Adamietz IA, Zieren J, Fakhrian K. Evaluating the Effect of Micropump[©] Position,
- 546 Internal Pressure and Doxorubicin Dosage on Efficacy of Pressurized Intra-peritoneal
- 547 Aerosol Chemotherapy (PIPAC) in an Ex Vivo Model. Anticancer Res. 2016
 548 Sep;36(9):4595-600. doi: 10.21873/anticanres.11008. PMID: 27630300.
- 549 25. Piao J, Park SJ, Lee H, Kim J, Park S, Lee N, Kim SI, Lee M, Song G, Lee JC, Kim HS;
- 550 KORIA TRIAL GROUP. Ideal Nozzle Position During Pressurized Intraperitoneal
- 551 Aerosol Chemotherapy in an Ex Vivo Model. Anticancer Res. 2021 Nov;41(11):5489-

552 5498. doi: 10.21873/anticanres.15362. PMID: 34732419.

- 553 26. Mun J, Park SJ, Kim HS. Rotational intraperitoneal pressurized aerosol chemotherapy in a
- 554 porcine model. Gland Surg. 2021 Mar;10(3):1271-1275. doi: 10.21037/gs-2019-ursoc-11.
- 555 PMID: 33842275; PMCID: PMC8033043.

559

- 27. Park SJ, Lee EJ, Lee HS, Kim J, Park S, Ham J, Mun J, Paik H, Lim H, Seol A, Yim GW,
 Shim SH, Kang BC, Chang SJ, Lim W, Song G, Kim JW, Lee N, Park JW, Lee JC, Kim
 HS: KoRIA* trial group. Development of rotational intraperitoneal pressurized aerosol
- 558 HS; KoRIA* trial group. Development of rotational intraperitoneal pressurized aerosol

chemotherapy to enhance drug delivery into the peritoneum. Drug Deliv. 2021

- 560 Dec;28(1):1179-1187. doi: 10.1080/10717544.2021.1937382. PMID: 34121568; PMCID:
 561 PMC8204987.
- 562 28. Braet H, Andretto V, Mariën R, Yücesan B, van der Vegte S, Haegebaert R, Lollo G, De
 563 Smedt SC, Remaut K. The effect of electrostatic high-pressure nebulization on the

Kockelmann et al. - Version V3

564	stability, activity and ex vivo distribution of ionic self-assembled nanomedicines. Acta
565	Biomater. 2023 Aug 19:S1742-7061(23)00492-0. doi: 10.1016/j.actbio.2023.08.027. Epub
566	ahead of print. PMID: 37598790.
567	29. Eveno C, Jouvin I, Pocard M. PIPAC EstoK 01: Pressurized IntraPeritoneal Aerosol
568	Chemotherapy with cisplatin and doxorubicin (PIPAC C/D) in gastric peritoneal
569	metastasis: a randomized and multicenter phase II study. Pleura Peritoneum. 2018 Jun
570	21;3(2):20180116. doi: 10.1515/pp-2018-0116. PMID: 30911659; PMCID:
571	PMC6405009.
572	30. Mortensen MB, Glehen O, Horvath P, Hübner M, Hyung-Ho K, Königsrainer A, Pocard
573	M, Reymond MA, So J, Fristrup CW. The ISSPP PIPAC database: design, process,
574	access, and first interim analysis. Pleura Peritoneum. 2021 Apr 22;6(3):91-97. doi:
575	10.1515/pp-2021-0108. PMID: 34676282; PMCID: PMC8482445.

Kockelmann et al. - Version V3

577 Figures and Tables

578	Table 1:	Toxicological	analyses	after nebulization	of chemotherapy	with the MDN
		0	2		12	

	Doxorubicin + Cisplatin	Oxaliplatin
HSGC-MS analysis for Volatile Organic Compounds	Not detected	Not detected
GC-MS analysis for Semi-Volatile Organic Compounds		
 1,6,11,16-Tetraoxacycloeicosane 1,6,11,16,21-Pentaoxacyclopentacosane 	Not detected Not detected	0.03 μg/ml 0.04 μg/ml
LC-MS analysis for Non-Volatile Organic Compounds		
 Cyclic polybutylene glycol (C20) Cyclic polybutylene glycol (C24) Cyclic polybutylene glycol (C32) 	0.144 μg/ml 0.246 μg/ml 0.083 μg/ml	0.131 µg/ml 0.123 µg/ml 0.045 µg/ml
ICP-MS analysis for inorganic elements		
- Cu - Fe - Mn	0.049 μg/ml 0.057 μg/ml 0.015 μg/ml	Not detected 0.011 µg/ml 0.014 µg/ml
IC analysis for anions		
 Acetates Fluorides Chlorides Bromides Nitrites Nitrates Sulfates Phosphates 	Not detected Not detected Not detected Not detected Not detected Not detected Not detected Not detected	Not detected Not detected Not detected Not detected Not detected Not detected Not detected Not detected

579

580	Legend: HSGC-MS = Head-space Gas Chromatography coupled with Mass Spectrometry;
581	GC-MS = Gas Chromatography coupled with Mass Spectrometry; LC-MS = Liquid phase
582	$chromatography \square coupled to a Mass Spectrometer; ICP-OES = Inductively Coupled Plasma$
583	Atomic Emission Spectrometry; $IC = Ion$ Chromatography; $Cu = Cupper$; $Fe = Ferrum$; Mn
584	= Manganese

Kockelmann et al. - Version V3

586 Figure 1: Ex vivo evaluation of the optimal position of the MDN in the 12-mm trocar



587

Legend: A = MDN inserted into a 12 mm balloon trocar. The position of the MNN head must be checked visually so that the lateral nozzles do not nebulize into the trocar. White triangles mark the distal end of the trocar. Note that the trocar is angled 15° at the distal end. Black arrows point to the horizontal nozzle openings. These should protrude at least 7 mm beyond the most distal end of the trocar (left white arrow). B = MDN inserted into a 12 mm balloon trocar. The black arrow points to the sterile rubbering ring pulled over the nebulizer shaft and that rests on the trocar head to avoid gliding of the nebulizer in the trocar.

- 595
- 596
- 597
- 598
- 599
- 600

- 602
- 603

Kockelmann et al. - Version V3

604 **Figure 2:** Periumbilical position of the MDN for optimized nebulization



606 Legend: A = Sketch of infraumbilical position of the MDN for optimized nebulization of all

607 four nozzles; B = intraoperative view on the MDN head

608

Kockelmann et al. - Version V3

609 Figure 3: Representative MDN-PIPAC CT-peritoneography images of pig N° 1





611 Legend: A1-C1 = horizontal section planes; A2-C2 = coronal section planes. White triangles 612 indicate to contrast agent accumulation: A1-C1 = enter-enteric and paracolic left; A2 =613 subdiaphragmatic bilateral; B2 = homogeneous on the Glisson capsule, subhepatic and 614 interlobar; C2 = perigastric and perilienal

Kockelmann et al. - Version V3

615 **Table 2:** Baseline clinical characteristics of the patients with MDN-PIPAC

Variables	Total population
	(n = 21)
Age at first MDN-PIPAC (years, mean (range))	62 (38-86)
Primary origin (n)	
- Colo-Rectal	3
- UGI	6
- HPB	3
- MPM	2
- Ovarian	4
- Other	3
ECOG (n)	
- 0	5
- 1	16
Synchronous PSM (n)	10
Prior primary tumor resection (n)	17
Prior systemic chemotherapy lines (median, range)	2 (1-5)
Prior standard PIPAC applications before MDP-PIPAC (median, range)	1 (1-4)
Ongoing systemic chemotherapy between MDN-PIPAC procedures (n)	14
Time between primary and metachronous PSM diagnosis	
(months, median (range))	21 (2-56)

616

617 Legend: PIPAC = pressurized intraperitoneal aerosol chemotherapy; MDN = multi618 directional nebulizer; UGI = upper gastrointestinal; HPB = hepato- biliary tract; ECOG =
619 Eastern Cooperative Oncology Group performance status; PSM = peritoneal surface
620 malignancy